Based on this circumstantial evidence and on our observations, we propose that displacement of Cu2+ from the Zn2+-binding site of DAT may contribute to the therapeutic efficacy of Zn2+ in Wilson's disease. Here, SLC6A3 is linked to Wilson disease.